On October 7, GENSCRIPT BIO experienced an intraday decline of 14.61% in regular trading, trading at 41.58 Hong Kong dollars, following a historic high the previous day where its market value surpassed 100 billion Hong Kong dollars. The stock has seen a sharp correction amid profit-taking after a nearly 270% cumulative surge since early July, driven by AI-driven drug discovery momentum including a recent collaboration with Eli Lilly's AIDD platform TuneLab.

Market data shows that while institutions such as FMR LLC recently increased their holdings in late September, JPMorgan reduced its position by approximately 33.75 million shares on September 15, cashing out around 1.105 billion Hong Kong dollars, indicating some large investors are choosing to realize gains at high levels. Current market sentiment reflects growing divergence over valuation in the AIDD sector, with some views suggesting the stock price has fully priced in optimistic expectations and that valuation pressure could emerge if order growth slows or competition intensifies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)